Cell Line News and Research

RSS

Genetic background shapes outcomes in chromosome 16 deletion disorders

Individuals that share the same deletion of a portion of chromosome 16 are at risk of developing neurodevelopmental disorders, but some experience severe intellectual disability or developmental delay, while others may only exhibit milder psychiatric features like depression or anxiety.

5 May 2026

ISSCR urges NIH to continue support human embryonic stem cell research

The International Society for Stem Cell Research (ISSCR) has submitted a formal response to a Request for Information (RFI) issued by the National Institutes of Health (NIH) regarding its pause on new submissions to the NIH Human Embryonic Stem Cell (hESC) Registry and considerations to reduce reliance on hESCs in federally supported research.

25 Apr 2026

Kenyan bat coronavirus uses human CEACAM6 to enter cells, raising spillover concerns

Researchers screened a phylogenetically diverse panel of alphacoronavirus spike proteins and found that a heart-nosed bat coronavirus from Kenya can use human CEACAM6 to enter cells.

23 Apr 2026

Stem cell model recreates early human embryo with yolk sac

For the first time, a stem cell model has produced a structure resembling an early human embryo with a yolk-sac-like structure, from a single starting stem cell population and without direct genetic manipulation.

21 Apr 2026

New CellCelector CLD takes you from thousands of candidates to the top clone, faster

Sartorius announces the launch of the CellCelector CLD, an automated imaging and cell isolation platform designed to simplify and accelerate monoclonal cell line development (CLD).

From Sartorius 10 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

Where digital holographic microscopy complements fluorescence microscopy

Integrating Digital Holographic Microscopy with fluorescence techniques enhances live-cell imaging, preserving cellular integrity and improving assay accuracy.

From Park Systems 2 Apr 2026

New neural organoid system improves scalability and reproducibility for research

Neural organoids have been heralded as having huge potential for advancing our knowledge of the brain in several fields.

27 Mar 2026

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

A narrative review in Food Science & Nutrition examined studies published from 2000 to 2025 and found that camel milk contains bioactive compounds with potential glycemic, anti-inflammatory, gut, and other health benefits. It also stressed that raw, unpasteurized camel milk poses microbial and zoonotic risks, underscoring that safety remains a key part of the story.

25 Mar 2026

Pen-strep treatment rewires mechanical sensing in immune cells

Macrophages are central to mechanobiology research: their physical characteristics-stiffness, adhesion, and ECM (extracellular matrix) sensing-are inextricably linked to their phenotypic polarization and immune function.

13 Mar 2026

mAbxience selects Genedata Bioprocess to automate end-to-end CDMO workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

From Genedata AG 11 Mar 2026

Med14 protein drives GLP-1 benefits in pancreatic beta cells

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health.

6 Mar 2026

Optimized costimulatory domains boost tumor killing in CAR NK cells

Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12.

20 Feb 2026

Dual targeting strategy suppresses pancreatic cancer cell growth

A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."

10 Feb 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

RNA micelles enable targeted chemotherapy without immune toxicity

A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and other therapies directly to tumors, killing cancer cells without generating an immune response or toxicity-related side effects.

7 Feb 2026

Eosinophils suppress tumor growth and recurrence in chordoma

Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite advances in oncology, effective treatments for chordoma remain limited.

31 Jan 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

WuXi Biologics and Hanchorbio enter strategic partnership to advance next-generation bi- and multi-functional fusion protein pipeline

WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.

27 Jan 2026